Fundraising Fox
/Companies
Sign in

Elixirgentherapeutics

Baltimore, US · Delaware corporation · 3 known investors

Find your way into Elixirgentherapeutics

Sign up to see every warm intro you have to Elixirgentherapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Elixirgentherapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Elixir Therapeutics develops therapies for rare diseases and aging-related conditions using proprietary technologies, including ZSCAN4 for telomere extension in stem cell therapies and Bobcat mRNA for delivering large genes. The company is advancing clinical candidates for telomere biology disorders and Duchenne muscular dystrophy.

BiotechLongevityMedical Devices

Founders & leadership

MK
Minoru KoChief Scientific Officer
AKAKIHIRO KO
AKIHIRO KOExecutive

Board

HK
HIROAKI KOBAYASHIBoard director
JC
JEFFREY CLELANDBoard director
TW
THOMAS WHITEBoard director
SC
SHAUNA CALLAHANBoard director

Investors · 3

TEDCOlisted by TEDCOColumbia
UTEClisted by UTECTokyo

How we know: UTEC's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$34.1M disclosed across 8 rounds · 2018–2025

▶$4MraisedNov 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • HIROAKI KOBAYASHIDirector
  • THOMAS WHITEDirector
  • JEFFREY CLELANDDirector
  • MINORU KODirector
  • SHAUNA CALLAHANDirector
  • AKIHIRO KOExecutive Officer, Director
Offering amount
$4M
Amount sold
$4M
First sale
Oct 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.6MraisedApr 2025 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • AKIHIRO KOExecutive Officer, Director
  • MINORU KODirector
  • JEFFREY CLELANDDirector
  • THOMAS WHITEDirector
  • SHAUNA CALLAHANDirector
  • HIROAKI KOBAYASHIDirector
Offering amount
$3.6M
Amount sold
$3.6M
First sale
Mar 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$600KraisedFeb 2025 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • HIROAKI KOBAYASHIDirector
  • JEFFREY CLELANDDirector
  • AKIHIRO KOExecutive Officer, Director
  • THOMAS WHITEDirector
  • MINORU KODirector
  • SHAUNA CALLAHANDirector
Offering amount
$600K
Amount sold
$600K
First sale
Jan 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$7MraisedDec 2023 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Akihiro C KoExecutive Officer, Director
  • Minoru S.H. KoDirector
  • Hiroaki KobayashiDirector
  • Thomas K. WhiteDirector
  • Shauna CallahanDirector
  • Jeffrey ClelandDirector
Offering amount
$7M
Amount sold
$7M
First sale
Nov 2023
Incorporated
Corporation, Delaware, 2018
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedSep 2022 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Maiko KatadaeDirector
  • Minoru KoExecutive Officer, Director
  • Akihiro KoExecutive Officer, Director, Promoter
  • Shauna CallahanDirector
  • Hiroaki KobayashiDirector
  • Thomas WhiteDirector
Offering amount
$5M
Amount sold
$5M
First sale
Sep 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.2MraisedFeb 2021 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Akihiro KoExecutive Officer, Director
  • Minoru KoDirector
  • Hiroaki KobayashiDirector
  • Naonori KurokawaDirector
  • Thomas WhiteDirector
  • Shauna CallahanDirector
Offering amount
$5.5M
Amount sold
$4.2M
First sale
Feb 2021
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.7MraisedAug 2020 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Maiko KatadaeDirector
  • Minoru KoDirector
  • Akihiro KoExecutive Officer, Director
  • Naonori KurokawaDirector
Offering amount
$5.7M
Amount sold
$5.7M
First sale
Nov 2019
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedJun 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • AKIHIRO KOExecutive Officer, Director
  • MINORU S.H. KODirector
Offering amount
$4M
Amount sold
$4M
First sale
Jun 2018
Incorporated
Corporation, Delaware, 2017
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 1

Biogen IdecBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.

Companies working in the same space as Elixirgentherapeutics.

Frequently asked questions

What does Elixirgentherapeutics do?
Elixir Therapeutics develops therapies for rare diseases and aging-related conditions using proprietary technologies, including ZSCAN4 for telomere extension in stem cell therapies and Bobcat mRNA for delivering large genes. The company is advancing clinical candidates for telomere biology disorders and Duchenne muscular dystrophy.
Who are Elixirgentherapeutics's investors?
Elixirgentherapeutics's investors include Maryland TEDCO, TEDCO, UTEC.
How much funding has Elixirgentherapeutics raised?
Elixirgentherapeutics has disclosed $34.1M raised across 8 rounds.
Where is Elixirgentherapeutics headquartered?
Elixirgentherapeutics is headquartered in Baltimore, US.